Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment

Journal of Medical Virology

Volumn 85, Issue 3, 2013, Pages 441-448

  Pham, Tram N Q ^a   Lin, Dolly M H ^a   Mulrooney Cousins, Patricia M ^a   Churchill, Norma D ^a   Kowala Piaskowska, Arleta ^b   Mozer Lisewska, Iwona ^b   Machaj, Anna ^c   Pazgan Simon, Monika ^c   Zalewska, Malgorzata ^c   Simon, Krzysztof ^c   King, Dawn ^d   Reddy, S Bharati ^d   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d Eastern Health Canada   (Canada)

Author keywords

Chronic HCV infection; Gene expression profiles; HCV RNA in PBMCs

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 8; LAMBDA INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOID CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA VIRUS; VIRUS LOAD;

2',5'-OLIGOADENYLATE SYNTHETASE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CYTOKINES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LYMPHOCYTES; MALE; MIDDLE AGED; PROGNOSIS; RIBAVIRIN; RNA, VIRAL; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME; UBIQUITINS; VIRAL LOAD; YOUNG ADULT;

EID: 84873103549     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23481     Document Type: Article

References (30)

1. Akbar H, Idrees M, Butt S, Awan Z, Sabar MF, Rehaman I, Hussain A, Saleem S. 2011. High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients. Infect Genet Evol 11:1301-1305.
2. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, Boyer N, Martinot-Peignoux M, Valla D, Vidaud M, Marcellin P. 2008. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57:516-524.
3. Blackard JT, Kemmer N, Sherman KE. 2006. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. Hepatology 44:15-22.
4. Carreno V, Bartolome J, Castillo I, Quiroga JA. 2008. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 18:139-157.
5. Chang S, Kodys K, Szabo G. 2010. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology 51:35-42.
6. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. 2005. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128:1437-1444.
7. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Talloen W, Bollekens J, De Wit M, Scholliers A, Fried MW. 2011. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53:14-22.
8. Fried MW. 2011. The role of triple therapy in HCV genotype 1-experienced patients. Liver Int 31:58-61.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
10. Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF. 2010. Virus-host interactions in hepatitis C virus infection: Implications for molecular pathogenesis and antiviral strategies. Trends Mol Med 16:277-286.
11. Girard S, Shalhoub P, Lescure P, Sabile A, Misek DE, Hanash S, Brechot C, Beretta L. 2002. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 295:272-283.
12. He Q, Graham CS, Durante Mangoni E, Koziel MJ. 2006. Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. Liver Int 26:1100-1110.
13. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR. 2005. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42:724-731.
14. Hu KQ, Vierling JM, Redeker AG. 2001. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 8:1-18.
15. Jia Y, Wei L, Jiang D, Wang J, Cong X, Fei R. 2007. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8. J Gastroenterol Hepatol 22:1278-1285.
16. Mihm U, Herrmann E, Sarrazin U, von Wagner M, Kronenberger B, Zeuzem S, Sarrazin C. 2004. Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol 40:845-852.
17. Navaneethan U, Kemmer N, Neff GW. 2009. Predicting the probable outcome of treatment in HCV patients. Ther Adv Gastroenterol 2:287-302.
18. Pham TNQ, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. 2004. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78:5867-5874.
19. Pham TNQ, King D, MacParland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. 2008. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 134:812-822.
20. Pham TNQ, Mercer SE, Michalak TI. 2009. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 16:547-556.
21. Pham TNQ, Coffin CS, Michalak TI. 2010. Occult hepatitis C virus infection: What does it mean? Liver Int 30:502-511.
22. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. 2001. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 75:6209-6211.
23. Qu L, Lemon SM. 2010. Hepatitis A and hepatitis C viruses: Divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Sem Liver Dis 30:319-332.
24. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J, Rice CM, Edwards AM, McGilvray ID. 2006. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131:1584-1591.
25. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. 2011. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141:1220-1230.
26. Sarhan MA, Pham TNQ, Chen AY, Michalak TI. 2012. Hepatitis C virus infection of heuman T lymphocytes is mediated by CD5. J Virol 86:3723-3735.
27. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H. 2004. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 11:271-276.
28. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Gen 41:1105-1109.
29. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142:978-988.
30. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. 2011. Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417-2428.